Erasca reports Q3 2026 results, Fast Track status for ERAS-0015 in pancreatic cancer
Erasca said ERAS-0015 won FDA Fast Track Designation for metastatic pancreatic adenocarcinoma as it moves toward three potentially registration-enabling trials, with $947.8 million in cash as of September 30, 2026.
Erasca, Inc. announced on November 12, 2026 that the FDA had granted Fast Track Designation to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma in August 20261. The company said the designation is meant to support faster development and review for serious conditions with high unmet need, and allows for more frequent interactions with the FDA as the company moves ahead with its planned Phase 3 trial in pancreatic cancer1.
Erasca also outlined data presentations set for the 38th EORTC-NCI-AACR (ENA) Symposium, taking place November 18-20, 2026 in Barcelona. An oral plenary talk will present updated ERAS-0015 monotherapy results from the ongoing "AURORAS-1" Phase 1 trial, with a larger patient group and extended follow-up1. A poster will show nonclinical results on combining ERAS-0015 with ERAS-4001 against both active and inactive forms of KRAS, including synergistic effects seen in models driven by KRAS G12X mutations1.
Looking ahead, Erasca said it expects Phase 1 monotherapy expansion data and Phase 1 combination dose escalation data, including a panitumumab combination, in the first half of 2027, a potentially registration-enabling second-line-or-greater NSCLC trial to begin in the first half of 2027, a Phase 3 pivotal trial in first-line PDAC to start in 2027, and a Phase 3 pivotal trial in RASm NSCLC to start between the second half of 2027 and first half of 20281. For ERAS-4001, the company expects preliminary Phase 1 monotherapy safety, tolerability, pharmacokinetic and early efficacy data in the second half of 2026, with expansion and combination cohorts planned for 20271.
On finances, Erasca reported cash, cash equivalents, and marketable securities of $947.8 million as of September 30, 2026, up from $341.8 million at the end of 20251, and said it expects this to be enough to fund the milestones listed in the release1. The company also noted it completed an upsized public offering in July 2026 that raised about $632.5 million in gross proceeds1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.